Presentation of Preliminary Results From Boston Scientific PREVAIL Clinical Trial Now Available
NATICK, Mass., March 9, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at http://www.tctmd.com/show.aspx?id=118115. PREVAIL evaluates the safety and efficacy of the WATCHMAN® Left Atrial Appendage (LAA) Closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy.
The company inadvertently broke the American College of Cardiology (ACC) embargo policy surrounding the PREVAIL clinical trial data, which were to be presented at the 62nd Annual Sessions of the American College of Cardiology in the Late-Breaking Clinical Trial presentation on Saturday, March 9, 2013. As a result of the inadvertent error, ACC canceled the presentation.
"Boston Scientific considers scientific exchange in a peer-reviewed setting to be of the utmost importance and we deeply regret that the data were not shared at ACC," said Kenneth Stein , M.D., chief medical officer, Cardiac Rhythm Management, Boston Scientific.
In the United States, WATCHMAN is an investigational device, limited by applicable law to investigational use and not available for sale.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com.